Biomarker Expression in PBMCs for Hepatitis B Treatment Response

A clinical study dataset likely contains gene expression levels for ADAR1, N4BP1, and PSME1 in peripheral blood mononuclear cells (PBMCs) from HBeAg-negative chronic hepatitis B patients. The data was collected by Hao Pang in a prospective study where patients were treated with Peg-IFN-α and followed for 48 weeks. The dataset was last updated on April 13, 2026.

Use Cases

• Predicting virological response to Peg-IFN-α treatment based on ADAR1, N4BP1, and PSME1 mRNA levels.
• Predicting serological response (HBsAg clearance) based on dynamic changes in biomarker expression.
• Building diagnostic models using ROC curve analysis and AUC values for the three biomarkers.
• Conducting multivariate analysis to identify independent factors associated with therapeutic response.

Strengths

• Includes specific performance metrics for biomarkers, such as an AUC of 0.9230 for ADAR1 predicting VR at week 24.
• Based on a prospective clinical study with defined patient groups (VR/NVR, SR/NSR) and a 48-week follow-up.
• Licensed under CC-BY-4.0 for open sharing and reuse.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• The dataset is very small at 18.6 KB, indicating limited scope.

Provenance

Source

figshare, author Hao Pang.

Collection Method

Data likely gathered from a prospective clinical trial (identifier 2023−311) using real-time quantitative PCR on patient PBMCs.

Time Range

Treatment and follow-up period of 48 weeks for the study.

Freshness

Last updated 2026-04-13 04:36:09; freshness should be verified.

Geography

null